Skip to content | Change text size
 

Michael Dooley

Photo of Mr Dooley

Professor of Clinical Pharmacy (and Director of Pharmacy, Bayside Health)

BPharm, Vic.Coll.Pharm.; Grad.Dip.Hosp.Pharm, Vic.Coll.Pharm.

Phone: 9276-2408
Fax: 9276-3305
E-mail: M.Dooley@alfred.org.au

Research Interests

  • Method for dosage prediction in obese patients
  • Drug handling and kinetics
  • Outcome measures for clinical pharmacy services
  • Clinical pharmacy services in disease management
  • Drug therapies for malignancy and symptom control
  • Medication safety and use in the aged

Recent Awards

  • 2004 Society of Hospital Pharmacists of Australia Clinical Pharmacy Award
  • 2004 Australian Council on Healthcare Standards Gold Medal Award
  • 2003 Society of Hospital Pharmacists of Australia GSK Medal of Merit
  • 2002 National ACHS Medication Safety Award 2002. Reduction in dispensing errors as a consequence of near-miss identification system.
  • 2002 Clinical Oncological Society of Australia 29th Annual Meeting 2002 Best of the Best contributed paper
  • Poole SG, Dooley MJ. Journal of Oncology Pharmacy Practice Best Practice Paper Award 2001
  • International Society of Oncology Pharmacy Practitioners Clinical Pharmacy Award 2000.
  • Various poster and paper awards at SHPA conferences: 1987, 1996,1997,1998, 1999, 2000, 2001

Recent Grants

  1. Dooley MJ, Spencer A. Review of filgrastim usage in acute myeloid leukaemia. Amgen Australia. 2005: $15,000
  2. Dooley MJ. Van De Vreede M, Lubliner M, et al  Clinical study for the identification of barriers to the uptake of premixed infusions: potassium chloride. Baxter Healthcare. 2005-2006: $97,000
  3. Bonollo M, Fiddes K, Dooley MJ, Stell R. Piloting integration of a clinical pharmacist into a disease management unit. Department of Human Services Better Skills, Best Care Health Workforce Pilot Projects. ($29,300) 2005
  4. Dooley MJ, Schwarer A. Impact of mucositis on costs associated with bone marrow transplantation. Amgen Australia. 2005: $18,000
  5. Scuteri J, Kinrade W, Riley S, Baron M, Skene M, Parrott K, Fodero L , Nation RL, Dooley MJ. Development, implementation and evaluation of funding model options for dispensing of pharmacotherapies for opioid dependence in community pharmacy. Pharmacy Guild of Australia. ($500,000) 2004/05
  6. Nation RL et al. Third Community Pharmacy Agreement Research and Development Grants Program Pharmacy Guild. Improving medication management of palliative care patients: enhancing the role of community pharmacists.($218,713)
  7. Dooley MJ, Poole SG. Opioid error prevention program. Safety in Practice 2001 ($9,800)
  8. Dooley MJ, Zalcberg J, Woodcock D, et al. Decision Support for Electronic Prescribing and Medication Administration in Oncology. Quality Improvement and Best Practice Funding 2001 Department of Human Services ($598,000)
  9. Slavin M, Thursky K, Dooley MJ, et al. Antibiotic Guidelines and Decision Support Systems for Infections in Cancer Patients. Quality Improvement and Best Practice Funding 2001 Department of Human Services. ($220,000)
  10. Dooley MJ. Risk management: contribution of clinical pharmacy services. Society of Hospital Pharmacists of Australia Australia. Bristol-Myers Squibb Clinical Pharmacy Research Grant. 2001 ($AUS 8,000)
  11. Carroll M, Galbraith K, Dooley MJ. Clinical pharmacy technicians - opportunity for development and standardisation. Society of Hospital Pharmacists of Australia. Abbott Australasia Hospital Pharmacy Research Grant 2001 ($AUS 10,000)

Publications

  1. Hussainy S, Beattie J, Nation RN, Dooley MJ, Fleming J, Wein S, Pisasale M, Scott W, Marriott J. Palliative care for patients with cancer: What are the educational needs of community pharmacists? Supp Care Cancer 2006, 14: 177-184
  2. Dooley MJ, Poole SG. Limitations of the Wright formula in estimating renal function. Annals of Oncology 2005; 16: 989 - 990
  3. Yu K, Nation RN, Dooley MJ. Multiplicity of medication safety terms, definitions and functional meaning: when is enough enough? Quality and Safety in Health Care 2005, 14(5):358-63
  4. Worth L, Dooley MK, Slavin M, et al. An analysis of the utilization of chemoprophylaxis against pneumoncystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 2005; 92: 876-872 
  5. Society of Hospital Pharmacists of Australia Committee of Specialty Practice in Clinical Pharmacy. Standards of Practice for Clinical Pharmacy. Pharm Pract Res 2005; 35: 122-46
  6. Duffell SB, Dooley MJ, Green B, Poole SG, Kirkpatrick CMJ. A standard weight descriptor for dose adjustments in obese patients. Clin Pharmacokinet 2004; 43: 1167-1178
  7. Brien J, Gilbar P, Dooley MJ. Inadvertent intrathecal administration of vincristine: are we fulfilling our roles as oncology pharmacists? J Oncol Pharm Pract 2004; 10: 187-189
  8. Dooley MJ. New oral therapies for cancer. Pharmacy News 2004
  9. Dooley MJ, Singh S, Rischin D. Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function. Br J Cancer 2004; 90: 991-995
  10. Lau P, Stewart K, Dooley MJ. The ten most common adverse drug reactions (ADRs) in oncology patients - do they matter to you?. Support Care Cancer 2004; 12: 626-633
  11. Raynor C.R., M.J. Dooley, and R.L. Nation. Antivirals for HIV. In: Schentag, J.J., L.M. Shaw, W.E. Evans, M.E. Burton editors). Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 4th Ed. 2004  
  12. Dooley MJ, Singh S, Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer 2004; 12; 653-656
  13. Dooley MJ, Allen KB, Doecke CJ, Galbraith KJ, Taylor GR, Bright J, Carey DL. A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals. Br J Clin Pharmacol 2004; 57: 513-521
  14. Poole SG, Dooley MJ. Off-label prescribing in oncology. Support Care Cancer 2004; 12: 302-305
  15. Stefanou A, Dooley MJ. The Vincotube System: A design solution to prevent the accidental administration of intrathecal vinca alkaloids. J Clin Oncol 2004; 22: 965-966
  16. Dooley MJ, Lee D, Marriott J. Practitioner’s sources of clinical information on complementary and alternative medicine (cam) in the oncology setting. Support Care Cancer 2004; 12: 114-119
  17. Burnett D, Dooley MJ, Wall D. Cell-based therapies – a role for pharmacy technicians. J Pharm Pract Res 2003; 33: 296-298
  18. Dooley MJ. Clinical pharmacy practice guidelines: Society of Hospital Pharmacists of Australia. Encyclopedia of Clinical Pharmacy, 1st Ed.; Joseph DiPiro, Ed.; Marcel Dekker, Inc.: New York, 2003.
  19. Dooley MJ. Looking beyond the immediate: challenge of clinical practice and research. J Pharm Pract Res 2003; 33: 302-304.  
  20. Moloney M, Prince HM, Slavin M, Seymour JF, Dooley MJ. Dosing Schedule of Oral Valacylovir for Prevention of Herpes Simplex Virus. Bone Marrow Transplantation 2003; 32: 1035
  21. Carroll M, Galbraith K, Dooley MJ. Utilisation of pharmacy technicians in Australian Hospitals. J Pharm Pract Res 2003; 
  22. Dooley MJ, Poole SG. The ongoing myth of a relationship between body surface area and glomerular filtration rate. J Oncol Pharm Pract 2003; 9: 43
  23. Dooley MJ, Singh S. Publication Rate for Abstracts Presented at the 24th Federal Conference. J Pharm Pract Res 2003; 33: 111-113
  24. Stefanou A, Dooley MJ. A Simple Method to Eliminate The Risk Of Inadvertent Intrathecal Vincristine Administration. J Clin Oncol 2003; 21: 2044
  25. Dooley MJ. Prescribing of warfarin and brand selection. J Pharm Pract Res 2003; 32: 259-260
  26. Dooley MJ. Strategies for safer prescribing of warfarin. Aust Presc 2003;26: 27
  27. Lau P, Stewart K, Dooley MJ. Hospital Admissions Resulting from Preventable Adverse Drug Reactions.  Ann Pharmacother 2003; 37: 303-304
  28. Zalcberg JC, Harsley SR, Dooley MJ, Variability in administration of 5-fluorouracil and folinic acid in standard treatment regimens for advanced colorectal cancer. Internal Medicine Journal 2002; 32: 1-3
  29. Dooley MJ, PL Lu. Hospital pharmacists fail to contribute to the quality use of medicines mapping project. J Pharm Prac Res 2002; 32: 141-2
  30. Poole SG, D Rischin, Dooley MJ. A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99m DTPA clearance) in cancer patients. Annals of Oncology 2002; 13: 949-955
  31. Aranda S, Dooley MJ, Wells K, Leahy M, Marvan E, Pollard A. The prevention and early detection of complications of oral mucositis. Health Promotion Strategies Bulletin 2002, 23; 18-20
  32. Dooley MJ, Poole SG, Rischin D, Webster LK. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 2002; 38: 244-51 
  33. Dooley MJ, Wilks J, Streater J. Strategy for identification on "near miss' events and improving dispensing accuracy. Aus J Hosp Pharm 2001; 31: 125-128
  34. Aranda S, Dooley MJ, Wells K, Leahy M, Marvan E, Pollard A. Prevention and early detection of oral mucositis in a cancer setting. Cancer Forum 2001; 25: 13-15
  35. Dooley MJ, Poole SG. Correlation between body surface area and glomerular filtration rate. Cancer Chemo Pharmacol 2000; 46; 523-526.
  36. Dooley MJ, Galbraith K, Burgess N, McLennan DN. Multicentre Pilot Study of a Standard Approach to Document Clinical Pharmacy Activity. Aust J Hosp Pharm 2000; 30: 150-6
  37. Hetherington N, Dooley MJ. Potential for patient harm from intrathecal medication containing preservatives. Med J Aus 2000; 174: 141-3
  38. Lau P, Dooley MJ, Stewart K. Recruitment of oncology patients for an adverse drug reaction study. Aust J Hosp Pharm 2000; 30: 175
  39. Poole SG, Dooley MJ. Establishing a baseline incidence of adverse drug reactions in hospitalised oncology patients. J Oncol Pharm Pract 2000; 6: 55-60
  40. Dooley MJ, Vernon JB.  Reproducibility of treatment methodologies detailed in contemporary published clinical trial reports. J Oncol Pharm Pract 2000; 6: 50-54
  41. McLennan DN, Dooley MJ. Documentation of clinical pharmacy activities. Aust J Hosp Pharm 2000; 30: 6-9
  42. Dooley MJ, Harsley S, Zalcberg J. Recommendations for the administration of 5-fluorouracil in colorectal cancer. The Australian experience. J Oncol Pharm Pract 2000: 6; 27.
  43. Dooley MJ et al. Guidelines for the Handling of Cytotoxic Agents 5th Ed, Peter MacCallum Cancer Institute 1999.
  44. McLennan DN, Dooley MJ, Brien JE. Beneficial clinical outcomes resulting from pharmacists interventions. J Oncol Pharm Pract 1999: 5: 184-189
  45. Harsley SR, Dooley MJ Transdermal fentanyl patch versus subcutaneously infused morphine – a cost comparison. Cancer Forum 1999; 23: 60.
  46. McLennan DN, Dooley MJ, Brien JE. ICD-10-AM activity codes - an opportunity for standardisation. Aust J Hosp Pharm 1999: 29; 381-384.
  47. Vernon J Dooley MJ. Reproducibility of published protocols in current oncology literature. Cancer Forum 1999; 23: 61.
  48. Poole SG, Dooley MJ. Drugs in ambulatory infusion devices: The appropriate temperature for stability testing. Aust J Hosp Pharm 1999; 29: 328-9.
  49. McLennan DN, Dooley MJ, Brien JE. Beneficial clinical outcomes resulting from pharmacists’ interventions. Cancer Forum 1999; 23:2.   
  50. Bingham JM, Dooley MJ. EXTRA – Extravasation Treatment Record Database: A database to record and review cytotoxic drug extravasation events. Aust J Hosp Pharm 1998; 28: 89-93.
  51. Brien JA, Poole S, Harsley S, Hetherington N, Dooley MJ. Variability in Carboplatin Dose Estimation. J Oncol Pharm Pract 1998; 4: 46. 
  52. Jeffrey AL, Dooley MJ, Harsley SR. The Effect of Gemcitabine on Liver Function Tests (LFTs). J Oncol Pharm Pract 1998; 4: 48.
  53. Dooley MJ. Avery’s Drug Treatment 4th Edition: Book Review. Aust J Hosp Pharm 1997; 27: 468-9.
  54. Dooley MJ et al. Society of Hospital Pharmacists of Australia Committee of Specialty Practice in Clinical Pharmacy. Standards of Practice for Clinical Pharmacy. In: Johnstone JM, Vienet MD, editors. Practice Standards and Definitions. The Society of Hospital Pharmacists of Australia. Melbourne: SHPA, 1996.
  55. Corollo C, Dooley MJ, Sidaram B, Chapman BR. Determination of Insulin Concentrations in Plastic Infusion Systems. Aust J Hosp Pharm 1995; 25: 129-35.